1–3 of 3 results for David M. Brown
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
MACRA, MIPS, and Meeting Quality Measures